Detecting Opioid Use Disorder in Health Claims Data With Positive Unlabeled Learning.

Kumar P, Moomtaheen F, Malec SA, Yang JJ, Bologa CG, Schneider KA, Zhu Y, Tohen M, Villarreal G, Perkins DJ, Fielstein EM, Davis SE, Matheny ME, Lambert CG. Detecting Opioid Use Disorder in Health Claims Data With Positive Unlabeled Learning. IEEE journal of biomedical and health informatics. 2025 Feb 1; 29(2):750-757, DOI: 10.1109/JBHI.2024.3515805.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

Accurate detection and prevalence estimation of behavioral health conditions, such as opioid use disorder (OUD), are crucial for identifying at-risk individuals, determining treatment needs, monitoring prevention and intervention efforts, and recruiting treatment-naive participants for clinical trials. The availability of extensive health data, combined with advancements in machine learning (ML) frameworks, has enabled researchers to employ various ML techniques to predict or identify OUD within patient health data. Ideally, we could directly estimate the prevalence, or the proportion of a population with a condition over time. However, underdiagnosis and undercoding of conditions in patient health records make it challenging to determine the true prevalence of these conditions and to identify at-risk patients with less severe conditions who are more likely to be missed. Consequently, patients without diagnoses may comprise positive and negative examples for a given condition. Treating all undiagnosed (uncoded) patients as negative when applying ML methods can introduce bias into models, affecting their predictive power. To address this issue, we employed Positive Unlabeled Learning Selected Not At Random (PULSNAR), a Positive and Unlabeled (PU) learning technique, to estimate the probability of a given patient having OUD during a time window and the overall population prevalence of OUD. In a sample of 3,342,044 commercially insured US patients with at least one opioid prescription filled, PULSNAR estimated that 5.08% of patients have a cumulative prevalence of OUD over a 2-5 a observation period, compared to the 1.35% with a recorded OUD diagnosis, with 73.5% of cases not diagnosed/coded. The prevalence estimates provided by PULSNAR are consistent with those reported in other studies.